So many scenarios in herpetic eye disease

Authors

  • Petja Vassileva Specialized Eye Hospital for Active Treatment “Acad. Pashev”
  • Yordanka Kirilova Specialized Eye Hospital for Active Treatment “Acad. Pashev”

DOI:

https://doi.org/10.31288/oftalmolzh202424048

Keywords:

latent herpetic infection, antiherpetic drugs, keratoplasty in corneal perforation, epidemiology of herpetic eye disease (HED)

Abstract

Human herpes infections are a major cause of morbidity worldwide. Herpes
Simplex Virus (HSV) and Varicella Zoster Virus (VZV) are frequent causes of
ocular pathology. Ocular herpes is a recurrent disease, and its complications may lead to blindness. Herpetic viral infection is characterized by its ability to remain latent in the nervous system. Reactivation from the ophthalmic branch of the trigeminal ganglion may lead to recurrent attacks.
Ocular herpes is a disastrous disease causing suffering and anxiety to millions of people, and also represents important economic burden. Recently the incidence of varicella zoster virus (VZV) is increasing for unknown reasons. Published data demonstrate also that more that 50% of patients with ocular and systemic manifestation of VZV are younger than 60 years and immunocompetent. We analyze retrospectively 160 consecutive patients with ocular herpes treated at our referral specialized eye hospital, and proposed original approach to different
scenarios of disease development.

References

Al-Dujaili LJ, Clerkin PP, Clement C, McFerrin HE, Bhattacharjee PS et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol. 2011; 6(8), 877-907. https://doi.org/10.2217/fmb.11.73

Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK et al. Trends in herpes simplex virus type 1 and 2 seroprevalence in the United States, JAMA. 2006. 269(8): 964-973. https://doi.org/10.1001/jama.296.8.964

McCormick I, James C, Welton NJ, Mayaud P, Turner KME, Gottlieb SL, Foster A, Looker KJ.. Incidence of herpes simplex virus keratitis and other ocular disease: global review and estimates. Ophthalmic Epidemiol. 2022 Aug;29(4):353-362. https://doi.org/10.1080/09286586.2021.1962919

Roizman B, Knipe DM, Whitley RJ. Herpes Simplex Viruses. In: Knipe D. M. and Howley P. M. Eds, Fields Virology. New York, NY, Lip- pincott Williams & Wilkins. 2007; 2: 2501-2601.

Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis, Cornea. 1999; 18(2): 127-143. https://doi.org/10.1097/00003226-199903000-00001

Thygeson P. Historical observation on herpetic keratitis, Surv. Ophthalmol. 1976; 21: 82-90. https://doi.org/10.1016/0039-6257(76)90084-9

Loewenstein A. Herpes Corneæ and Virus Infection, Glasgow Med. J. 1944; 141(2): 54-62.

Sawtell NM. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 1977; 71(7): 5423-5431. https://doi.org/10.1128/jvi.71.7.5423-5431.1997

Hengel H. Common Characteristics and Distinct Features of Human Pathogenic Herpesviruses. In: Sundmacher R. (ed.) Color Atlas of Herpetic Eye Diseases, Springer, 2009. Berlin, Heidelberg.

Faria-E-Sousa SJ, Antunes-Foschini R. Herpes simplex keratitis revisited. Arq Bras Oftalmol. 2021 Jul 14;84(5):506-512. https://doi.org/10.5935/0004-2749.20210082

Valerio GS, Lin CC. Ocular manifestations of herpes simplex virus. Curr Opin Ophthalmol. 2019 Nov;30(6):525. https://doi.org/10.1097/ICU.0000000000000618

James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 2020; 98(5): 315-329. https://doi.org/10.2471/BLT.19.237149

Kaye S, Choudhary A. Herpes simplex keratitis, Prog. Retin. Eye Res. 2006; 25(4): 355-380. https://doi.org/10.1016/j.preteyeres.2006.05.001

Holland EJ, Schwartz JS. Classification of herpes simplex virus keratitis, Cornea. 1999; 18(2): 144-154. https://doi.org/10.1097/00003226-199903000-00002

Whitley RJ, Baron S. Herpes viruses. In: Medical Microbiology, 4th edition, Galveston (TX), University of Texas Medical Branch at Galveston, 1996. Chapter 68.

Brandt CR. Mixed ocular infections identify strains of herpes simplex virus. J. Virol. Methods. 1991; 35(2): 127-135. https://doi.org/10.1016/0166-0934(91)90128-M

Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM et al. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 1992; 166(5): 1153-1156. https://doi.org/10.1093/infdis/166.5.1153

Lundberg P, Welander P, Openshaw H, Nalbandian C, Edwards C et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation while an unlinked locus augments resistance of female mice. J. Virol. 2003; 77(21): 11661-11673. https://doi.org/10.1128/JVI.77.21.11661-11673.2003

Jouanguy E, Zhang S-Y, Chapgier A, Sancho-Shimizu V, Puel A et al. Human primary immunodeficiencies of type 1 interferons, Biochimie. 2007; 89(6-7): 878-883. https://doi.org/10.1016/j.biochi.2007.04.016

Lopez C. Genetics of natural resistance to herpes virus infections in mice. Nature. 1975; 258: 152-153. https://doi.org/10.1038/258152a0

Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons and CD8+ T cells maintain HSV-1 latency, Immunol. 2006; 36(1-3): 119-126. https://doi.org/10.1385/IR:36:1:119

Bloom DC. HSV LAT and neuronal survival. Int. Rev. Immunol. 2004; 23(1-2): 187-198. https://doi.org/10.1080/08830180490265592

Perng GS, Jones C. Towards an understanding of the herpes simplex virus type 1 latency reactivation cycle. Interdiscip. Perspect. Infect. Dis. 2010; 2010: 262415. https://doi.org/10.1155/2010/262415

Kennedy DP, Clement C, Arceneaux RL, Bhattacharjee PS, Huq TS et al. Ocular herpes simplex virus type 1: is the cornea a reservoir for viral latency or a fast pit stop? Cornea. 2011; 30(3): 251-259. https://doi.org/10.1097/ICO.0b013e3181ef241d

Toma HS, Murina AT, Areaux RG et al. Ocular HSV-1 latency, reactivation and recurrent disease, Semin. Ophthalmol. 2008; 23(4): 249-273. https://doi.org/10.1080/08820530802111085

Richter ER, Dias JK, Gilbert GE, Atherton SS. Distribution of herpes simplex virus type 1 and varicella zoster virus in ganglia of the human head and neck. J. Infect. Dis. 2009; 200(12): 1901-1906. https://doi.org/10.1086/648474

Fatahzadeh M. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007; 57(5): 737-763. https://doi.org/10.1016/j.jaad.2007.06.027

Gaynor BD, Margolis TP, Cunningham E. Advances in diagnosis and management of herpetic uveitis, Int. Ophthalmol. Clin. 2000; 40(2): 85-109. https://doi.org/10.1097/00004397-200004000-00008

Kaufman HE, Azcuy AM, Varnell ED, Sloop GD. HSV-1 DNA in tears and saliva of normal adults, Invest. Ophthalmol. Vis. Sci. 2005; 46(1): 241-247. https://doi.org/10.1167/iovs.04-0614

Remeijer R, Maertzdorf J, Doornenbal P, Verjans JM, Osterhaus AD. Herpes simplex virus 1 transmission through corneal transplantation. Lancet. 2001; 357(9254): 442. https://doi.org/10.1016/S0140-6736(00)04011-3

Vassileva P. Therapeutic behavior according to the type and stage of ocular herpes, Medinfo. 2013; 13(10): 40-47 [in Bulgarian].

Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am. J. Ophthalmol. 1999; 127(5): 531-536. https://doi.org/10.1016/S0002-9394(99)00089-6

Cunningham AL, Diefenbach RJ, et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 2006; 194(1): 11-18. https://doi.org/10.1086/505359

Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis, Cornea. 2001; 20(2): 123-128. https://doi.org/10.1097/00003226-200103000-00001

Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2′-deoxyuridine (IDU) in treatment of herpes simplex keratitis, Arch. Ophthalmol. 1962; 68: 235-239. https://doi.org/10.1001/archopht.1962.00960030239015

Sibley D, Larkin DFP. Update on Herpes simplex keratitis management. Eye (Lond). 2020 Dec;34(12):2219-2226. https://doi.org/10.1038/s41433-020-01153-x

Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis, Review, Cochrane Database Syst. 2015 Jan; 2015(1): CD002898. https://doi.org/10.1002/14651858.CD002898.pub5

Kaye D, Kaye KM, Aleissa M, Dionne B. Herpes zoster: a potentially dangerous but preventable disease, Healio, News, Infectious Disease, Vaccination. 2019

Cohen EJ, Hochman JS, Troxel AB, Colby KA, Jeng BH; ZEDS Trial Research Group. Zoster Eye Disease Study: Rationale and Design. Cornea 2022;1;41:5:562-571. https://doi.org/10.1097/ICO.0000000000002743

Minor M, Payne E. Herpes Zoster Ophthalmicus. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.

Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N. Engl. J. Med. 2005; 352: 2271-2284.

Poon SHL, Wong WHL, Lo ACY, Yuan H, Chen CF, Jhanji V, Chan YK, Shih KC. A systematic review on advances in diagnostics for herpes simplex keratitis. Surv Ophthalmol. 2021 May-Jun;66(3):514-530. https://doi.org/10.1016/j.survophthal.2020.09.008

Weber DJ. Prevention and control of varicella-zoster virus in hospitals. 2020 www.uptodate.com.

Vrcek I, Choudhury E, et al. Herpes Zoster Ophthalmicus: A Review for the Internist. Am. J. Med. 2017; 130(1): 21-26. https://doi.org/10.1016/j.amjmed.2016.08.039

Kennedy PGE, Cohrs RJ. Varicella-zoster virus human ganglionic latency: a current summary, Review. J. Neurovirol. 2010; 16(6): 411-418. https://doi.org/10.1007/BF03210846

Goldstein RS, Kinchington PR. Varicella Zoster Virus Neuronal La- tency and Reactivation Modeled in Vitro, Review. Curr. Top. Microbiol. Immunol. 2023; 438: 103-134. https://doi.org/10.1007/82_2021_244

Downloads

Published

2024-05-01

How to Cite

1.
Vassileva P, Kirilova Y. So many scenarios in herpetic eye disease. J.ophthalmol. (Ukraine) [Internet]. 2024 May 1 [cited 2024 May 19];(2):40-8. Available from: https://ua.ozhurnal.com/index.php/files/article/view/113

Issue

No. 2 (2024): Journal of Ophthalmology (Ukraine)

Section

Literature Review

License

Copyright (c) 2024 Petja Vassileva, Yordanka Kirilova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.